Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review ArticleExperimental StudiesR

Electrotransfer of RNAi-based Oligonucleotides for Oncology

SOPHIE CHABOT, SANDRINE PELOFY, AURELIE PAGANIN-GIOANNI, JUSTIN TEISSIE and MURIEL GOLZIO
Anticancer Research December 2011, 31 (12) 4083-4089;
SOPHIE CHABOT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SANDRINE PELOFY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AURELIE PAGANIN-GIOANNI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUSTIN TEISSIE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MURIEL GOLZIO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: muriel.golzio@ipbs.fr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

For more than a decade, there has been tremendous growth in our understanding of RNA interference (RNAi). The potent ability that small oligonucleotides have in gene silencing makes them desirable as novel cancer therapeutics, but many biological barriers exist for their efficient delivery into target cells or tissues. Electropulsation (EP) appears to be a promising method for cancer-associated gene therapy. EP is the direct application of electric pulses to cells or tissues that transiently permeabilize the plasma membranes, allowing efficient in vitro and in vivo cytoplasmic delivery of exogenous molecules. The present review reports on the type of therapeutic RNAi-based oligonucleotides that can be electrotransferred, the mechanism of their electrotransfer and the technical settings for pre-clinical purposes.

  • Electroporation
  • oligonucleotides
  • siRNA
  • miRNA
  • review

Difficulties with blocking therapeutic targets using conventional approaches have prompted many to consider using RNA interference (RNAi) as a new antitumor strategy (1). RNAi offers the possibility of targeting and silencing any pathological protein in a specific way (2). RNAi is mediated endogenously by microRNAs (miRNAs) (3) and experimentally by small silencing RNAs (siRNAs) (4). Both are small (~22 nt) noncoding RNAs that, once loaded into the RNA-induced silencing complex (RISC), bind to their target messenger RNA (mRNA) impairing its translation. As a result, gene expression is suppressed (5, 6).

The development of therapeutic RNAi-based oligonucleotides is now moving to a new stage that involves efficient tumor delivery. In fact, their physicochemical characteristics (i.e. large molecular weight and anionic charge) prevent passive diffusion across the plasma membrane of most cell types. Therefore, enhanced delivery methods are required to allow therapeutic oligonucleotides to enter cells while being biocompatible, safe, and targeted.

In this context, electropulsation (EP) is a promising non-viral biophysical method for in vitro and in vivo delivery of various molecules such as drugs (7) and nucleic acids (8, 9). EP was introduced in the 1960s (10) and consists of the application of an external electric field to target cells or tissues. Under calibrated electric conditions, it transiently destabilizes the plasma membrane, causing its permeabilization (11). The efficiency and convenience (i.e. ease of the procedure, low cost and speed) of this technique lead to its extensive in vivo use for a large number of both internal and surface organs and tissues (12, 13). Moreover, only very few side-effects have been reported (mostly superficial burn), emphasizing the innocuousness of this method for clinical use. In addition, no change in the expression profile of major tumor suppressor genes or oncogenes, of genes involved in the stability of DNA and no promotion of tumor genesis were detected. The expression of metastasis promoting genes was not increased after electrochemotherapy (14, 15). To date, several preclinical and clinical studies using EP for cancer treatment showed encouraging results demonstrating antitumor effectiveness (16-21).

This article reviews the type of therapeutic RNAi-based oligonucleotides that can be electrotransferred, the mechanism of their electrotransfer and the technical settings for clinical purposes.

RNAi-based Oligonucleotides Suitable for Electrotransfer

RNAi is an mRNA-targeted therapeutic that specifically targets and degrades mRNA using natural cellular mechanism (2). RNAi is a highly promising therapeutic approach for those tumors involving aberrant protein production. In fact, human clinical trials have been initiated to utilize RNAi potential for therapeutic purposes (Table I). However, these trials were dramatically hampered by difficulties in the delivery of RNAi-based oligonucleotides (22). EP appears to be well adapted for all kinds of RNAi-based oligonucleotides.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Current clinical trials for RNAi-based oligonucleotides.

Small silencing RNA (siRNA). SiRNA is engineered to precisely match the protein-encoding nucleotide sequence of the target mRNA. It associates with the RISC complex and the siRNA-associated RISC binds to the target mRNA through a base-pairing interaction and degrades it. RNAi-based experiments can suffer from lack of specificity due to silencing of non targeted genes unless a well designed sequence is used (23).

Although siRNA in vitro efficiency is high, its in vivo delivery remains a critical issue for its therapeutic development. A safe approach requests a direct transfer to the cytoplasm to avoid unwanted effects associated with the delivery pathways (24). EP has been used successfully for in vivo siRNA electrotransfer in a wide variety of tissues such as skin (25), muscle (26, 27), joint tissue (28, 29), eyes (30), brain (28), kidney (31). EP has also proved its efficacy in siRNA tumor electrotransfer (9, 32-34). In fact, tumor siRNA electrotransfer is much more efficient than the use of plasmid DNA. EP, as compared with other delivery methods such as hydrodynamic transfection, needs much smaller amounts of siRNA to be effective (27, 35) and increases its duration of action (35, 36). In addition, no tissue damage (27) or immune response were observed with EP, in contrast to other delivery technics (37).

MicroRNA (miRNA)-based oligonucleotides. Targeting pathways of human disease with miRNA-based drugs represents a novel and potentially powerful therapeutic approach (38). miRNAs play a role in numerous biological processes, including the immune response, cell-cycle control, metabolism, viral replication, stem cell differentiation and human development (39). miRNA expression or function is significantly altered in many disease states, including cancer (40, 41), cardiovascular diseases (42) and diabetes (43). Since miRNAs do not require perfect complementarity for target recognition, a single miRNA is able to regulate multiple messenger RNAs, in contrast to siRNA. Therefore miRNA-based therapy is anticipated to be highly efficacious. Depending on miRNA function and its status in diseased tissues, there are two approaches to developing miRNA-based therapy: use of antagonists or mimics. In many cases, tumor-suppressor miRNAs reactivation by synthetic miRNA mimics (44) or oncogene inhibition by antagonists (45) leads to a significant antitumor response, as long as an efficient delivery method is present.

Most of the published reports used systemic delivery (46, 47), which implies repetitive high-dose injections, associated with non-specific targeting and toxic side-effects or direct intra-tumor injection alone without any delivery system (48), with associated poor tumor uptake and high degradation by tumor nucleases. Recently, tumor electrotransfer of miRNA mimics has also been described in mice (49). By rescuing miR-143 expression with in vivo electrotransfer of mimic oligonucleotide, prostate cancer cell growth was abrogated. These data show that EP is effective in delivering therapeutic miRNA-based oligonucleotide to tumor tissue in vivo.

Chemically modified oligonucleotides. Due to its small size, RNAi-based therapy calls for robust and improved antisense oligonucleotide technology. Therefore, new generations of chemically modified oligonucleotides have been developed (50) including 2’-O-methyl, 2’-methoxyethyl, locked nucleic acids (LNA), and phosphorothiate linkages (51, 52). LNA oligonucleotide incorporation into a DNA or RNA oligomer improves the mismatch discrimination compared to unmodified reference oligonucleotide (53). In addition, LNA oligonucleotide is highly resistant to nuclease degradation and presents low toxicity for biological systems (54, 55). The most advanced miRNA-based oligonucleotide is an antagonist LNA specific to miR-122, which is currently in clinical phase II trial for patients infected with hepatitis C virus (56).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Electropulsation overcomes barriers to RNAi-based oligonucleotide therapy.

Little work has been performed on the delivery of these chemically modified oligonucleotides. Interestingly, we observed that LNA-DNA oligomer can be efficiently electrotransferred in vitro and in vivo (personal communication). The number or the position of LNA into the DNA sequence does not interfere with electrotransfer efficiency. However, electrotransferred phosphorothiate-modified LNAs spontaneously stacked to the membrane and strongly aggregated at the cell surface, rendering them less attractive for RNAi-based therapies (unpublished observation). Thus, if chemically modified oligonucleotides appear, in theory, to be promising for RNAi-based therapy, more work for their efficient delivery needs to be performed.

Mechanism of RNAi-based Oligonucleotide Electrotransfer

EP represents a very attractive delivery method (Table II) that has led to abundant literature. However, very little was known about the basic processes supporting the electrotransfer of RNAi-based oligonucleotides. Using a fluorescently labeled siRNA, we observed that after the electrotransfer, siRNA was distributed homogeneously throughout the cytoplasm of cultured tumor cells (57). Thus, upon EP, siRNA had immediate, free access to the cytoplasm allowing its direct interaction with the enzymatic machinery (RISC) and its mRNA target. In these experiments, no electrotransferred siRNA was observed in the nucleus of viable cells. Similar localization was observed in vivo in mice after intratumor injection of siRNA followed by EP (58).

It is well known that electrotransfer of plasmid DNA is a multistep process: electrophoretic migration towards the permeabilized membrane, insertion into the membrane, translocation across the membrane and migration towards the nucleus (59, 60) (Figure 1). Electrotransferred plasmid DNA is not spread into the cytoplasm as is observed for small molecules, such as anticancer drugs. Small molecules enter into the cell across permeabilized zones of the membrane facing both electrodes via the concentration gradient difference between the exterior and the cell interior by post pulse diffusion process (61) (Figure 1). In contrast, siRNA electrotransfer implies electrophoretic movements. However, contrary to plasmid DNA, where a complex between the DNA and the membrane results from pulse application (Figure 1), a direct transfer is present with siRNA. After pulse application no diffusion process, as occurs for drugs, occurs although the membrane is still permeabilized (57).

The mechanism of LNA electrotransfer appears to be closely similar to that for siRNA, meaning that LNA oligomer entry is driven by the electrophoretic forces (personal observation). Electrotransferred LNA is spread homogenously throughout the cytoplasm contrary to lipid-mediated transfection in which LNA oligomer is shown to be localized in the nuclear periphery in a punctate way, suggesting an endosomal distribution (55, 62, 63). More work is under way to characterize the mechanism and the potential of LNA electrotransfer for RNAi-based therapies.

Technical Designs

The basic instrumentation for EP comprises a pulse generator and specific electrodes. However, the definition of the electrical parameters and the design of the electrodes are crucial steps for efficient and safe electrotransfer into the tumor.

Electrical parameters. Electrical conditions are characterized by physical parameters: electric field intensity (E), number (N), duration (T) and frequency (F) of the electric pulses. These parameters are essential to achieve effective transfer while preserving cell viability and avoiding drastic effects on the patient (essentially superficial burns and muscle contractions). Depending on the size and nature of the molecule to be transferred, there are two types of electrical parameter settings: electrochemotherapy (ECT) and electrogenotherapy (EGT).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Mechanisms of electrotransfer. Small molecules mostly enter the cells by diffusion through both sides of the permeabilized membrane facing the electrodes after the pulse. Plasmid DNA, dragged by the electrophoretic forces, interacts with the permeabilized membrane at the cathode side and remains on the membrane for a few minutes before its translocation into the cytoplasm. SiRNA migrates electrophoretically during the pulse through the membrane only at the cathode side, resulting in direct cytosolic localization.

ECT is a treatment where a cytotoxic drug, such as cisplatin or bleomycin (low molecular weight), is usually intravenously injected, directly followed by pulse application to the tumor. This method uses high electric field intensity (kV/cm) of short duration (microseconds). ECT protocols (8 pulses of 100 μs at 1300 V/cm; 1 Hz) have been tested in human clinics to treat malignant cutaneous and subcutaneous melanoma (64). ECT has also been used successfully in veterinary medicine for treatment of feline sarcoma (65) and equine sarcoids (66). Interestingly, these settings were proven to be efficient for a clinical trial for plasmid delivery (20).

The EGT parameters allow the electrotransfer of macromolecules (e.g. nucleic acids) to the tissues. Compared to ECT, this procedure uses lower field intensity (V/cm) with longer duration (milliseconds) to increase the electrophoretic movement of the electrotransferred macromolecule during the pulse. This procedure also allows simple and efficient transfer of siRNA both in vitro and in vivo (58). In animal models, EGT has been performed in many different tissues: skeletal (67, 68), cardiac muscle (69), liver (70, 71), skin (72, 73), spleen (74), kidney (75), brain (76), joints (77) and tumor (58).

Other electrical settings are reported. They consist of combinations of pulses of high voltage and short duration (HV, permeabilizing pulse) (78) followed by low voltage and long duration non-permeabilizing pulses (LV, electrophoretic pulse). Study on the skeletal muscle of mice shows that the (HV-LV) pulse sequence leads to an efficient gene transfer, similar to the one obtained by use of EGT described above (79).

As yet, no standardized EGT electrical parameter settings exist, partially due to the fact that the tissue response to the electric pulses depends on its origin, shape and environment, but also on the type of electrodes used.

Choice of electrodes. The success of the EP technique is linked to the proper distribution of the electric field in the tumor which is dependent on the type of electrodes used. Numerous configurations of electrodes have been developed for therapeutic purposes: parallel plate, needle, contact wire etc. (80).

Parallel plate electrodes are used most frequently for subcutaneous tumor electrotransfer. This consists of placing the electrodes on both sides of the tumor prior to electric pulse delivery (81). This simple design has produced high response rates (70 to 85%) in animal studies and in clinical anticancer trials (82).Their limitation is that the tumor should fit into the inter-electrode space and that the high field at the contact of the electrode with the skin can induce superficial burns if sharp angles are kept in their design.

If plate electrodes have been shown to be more suited for the treatment of cutaneous tumor, needle electrodes are more efficient in intraoperative settings or for treating the deepest regions of cutaneous tumors (83). Needle electrodes are inserted through the skin allowing deeper penetration of the electric field into the tumor. However, with these electrodes, the electric field is heterogeneous as it is confined to the immediate proximity of the needles. A strong burning of the tissue in contact with the needles was reported. Several configurations are in development such as linear and circular arrays (83).

Contact wire electrodes have been proven to be very efficient and convenient when large tissue surfaces (several square centimeters) must be treated due to the ease of their use at the cutaneous level (80).

New designs of electrodes are under development in order to adapt the field distribution to the geometry of the tumor, enabling cancer cell permeabilization with minimum tissue damage. These improvements are based on numerical modeling but the irregular shape of the tumor and the heterogeneity of the surrounding layers make it difficult (84).

Conclusion

Since the discovery of the RNAi pathway, there has been an explosion of interest and knowledge in using this technology for clinical application. Although highly attractive as a therapeutic approach, several hurdles must be overcome to successfully introduce RNAi-based therapies into clinical practice. An efficient, safe and localized delivery to diseased cells and tissues must be obtained. Progress is being made in developing new delivery approaches to address these issues. However, the vast majority is still only applicable in vitro. In this context, EP is a promising biophysical strategy to target RNAi-based oligonucleotides to the correct tissue, to facilitate their cellular uptake and to give direct access to their cytoplasmic target. The EP technique is already capable of overcoming many of the delivery hurdles, as proven by its successful translation to clinical practice.

Acknowledgements

This work was supported by grants of the Ligue contre le Cancer, CNRS and FP7 oncomirs (Grant 201102).

  • Received October 14, 2011.
  • Revision received November 14, 2011.
  • Accepted November 15, 2011.
  • Copyright© 2011 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Bumcrot D,
    2. Manoharan M,
    3. Koteliansky V,
    4. Sah DW
    : RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719, 2006.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Fire A,
    2. Xu S,
    3. Montgomery MK,
    4. Kostas SA,
    5. Driver SE,
    6. Mello CC
    : Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811, 1998.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Lee RC,
    2. Feinbaum RL,
    3. Ambros V
    : The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854, 1993.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Tong AW,
    2. Zhang YA,
    3. Nemunaitis J
    : Small interfering RNA for experimental cancer therapy. Curr Opin Mol Ther 7: 114-124, 2005.
    OpenUrlPubMed
  5. ↵
    1. Bartel DP
    : MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Carthew RW,
    2. Sontheimer EJ
    : Origins and mechanisms of miRNAs and siRNAs. Cell 136: 642-655, 2009.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Cemazar M,
    2. Golzio M,
    3. Escoffre JM,
    4. Couderc B,
    5. Sersa G,
    6. Teissie J
    : In vivo imaging of tumor growth after electrochemotherapy with cisplatin. Biochem Biophys Res Commun 348: 997-1002, 2006.
    OpenUrlPubMed
  8. ↵
    1. Cemazar M,
    2. Golzio M,
    3. Sersa G,
    4. Hojman P,
    5. Kranjc S,
    6. Mesojednik S,
    7. Rols MP,
    8. Teissie J
    : Control by pulse parameters of DNA electrotransfer into solid tumors in mice. Gene Ther 16: 635-644, 2009.
    OpenUrlPubMed
  9. ↵
    1. Golzio M,
    2. Mazzolini L,
    3. Paganin-Gioanni A,
    4. Teissie J
    : Targeted gene silencing into solid tumors with electrically mediated siRNA delivery. Methods Mol Biol 555: 15-27, 2009.
    OpenUrlPubMed
  10. ↵
    1. Coster HG
    : A quantitative analysis of the voltage-current relationships of fixed charge membranes and the associated property of “punch-through”. Biophys J 5: 669-686, 1965.
    OpenUrlPubMed
  11. ↵
    1. Teissie J,
    2. Golzio M,
    3. Rols MP
    : Mechanisms of cell membrane electropermeabilization: a minireview of our present (lack of?) knowledge. Biochim Biophys Acta 1724: 270-280, 2005.
    OpenUrlPubMed
  12. ↵
    1. Wells DJ
    : Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther 11: 1363-1369, 2004.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Heller LC,
    2. Heller R
    : In vivo electroporation for gene therapy. Hum Gene Ther 17: 890-897, 2006.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Todorovic V,
    2. Sersa G,
    3. Mlakar V,
    4. Glavac D,
    5. Flisar K,
    6. Cemazar M
    : Metastatic potential of melanoma cells is not affected by electrochemotherapy. Melanoma Res 21: 196-205, 2011.
    OpenUrlPubMed
  15. ↵
    1. Mlakar V,
    2. Todorovic V,
    3. Cemazar M,
    4. Glavac D,
    5. Sersa G
    : Electric pulses used in electrochemotherapy and electrogene therapy do not significantly change the expression profile of genes involved in the development of cancer in malignant melanoma cells. BMC Cancer 9: 299, 2009.
    OpenUrlPubMed
  16. ↵
    1. Mir LM,
    2. Glass LF,
    3. Sersa G,
    4. Teissie J,
    5. Domenge C,
    6. Miklavcic D,
    7. Jaroszeski MJ,
    8. Orlowski S,
    9. Reintgen DS,
    10. Rudolf Z,
    11. Belehradek M,
    12. Gilbert R,
    13. Rols MP,
    14. Belehradek J Jr..,
    15. Bachaud JM,
    16. DeConti R,
    17. Stabuc B,
    18. Cemazar M,
    19. Coninx P,
    20. Heller R
    : Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 77: 2336-2342, 1998.
    OpenUrlCrossRefPubMed
    1. Sersa G,
    2. Stabuc B,
    3. Cemazar M,
    4. Miklavcic D,
    5. Rudolf Z
    : Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res 10: 381-385, 2000.
    OpenUrlCrossRefPubMed
    1. Gothelf A,
    2. Mir LM,
    3. Gehl J
    : Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 29: 371-387, 2003.
    OpenUrlCrossRefPubMed
    1. Sersa G,
    2. Miklavcic D,
    3. Cemazar M,
    4. Rudolf Z,
    5. Pucihar G,
    6. Snoj M
    : Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 34: 232-240, 2008.
    OpenUrlPubMed
  17. ↵
    1. Daud AI,
    2. DeConti RC,
    3. Andrews S,
    4. Urbas P,
    5. Riker AI,
    6. Sondak VK,
    7. Munster PN,
    8. Sullivan DM,
    9. Ugen KE,
    10. Messina JL,
    11. Heller R
    : Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26: 5896-5903, 2008.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Bodles-Brakhop AM,
    2. Heller R,
    3. Draghia-Akli R
    : Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther 17: 585-592, 2009.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Castanotto D,
    2. Rossi JJ
    : The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433, 2009.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Sigoillot FD,
    2. King RW
    : Vigilance and validation: Keys to success in RNAi screening. ACS Chem Biol 6: 47-60, 2011.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Heidel JD,
    2. Hu S,
    3. Liu XF,
    4. Triche TJ,
    5. Davis ME
    : Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 22: 1579-1582, 2004.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Zhang L,
    2. Nolan E,
    3. Kreitschitz S,
    4. Rabussay DP
    : Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. Biochim Biophys Acta 1572: 1-9, 2002.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Kishida T,
    2. Asada H,
    3. Gojo S,
    4. Ohashi S,
    5. Shin-Ya M,
    6. Yasutomi K,
    7. Terauchi R,
    8. Takahashi KA,
    9. Kubo T,
    10. Imanishi J,
    11. Mazda O
    : Sequence-specific gene silencing in murine muscle induced by electroporation-mediated transfer of short interfering RNA. J Gene Med 6: 105-110, 2004.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Golzio M,
    2. Mazzolini L,
    3. Moller P,
    4. Rols MP,
    5. Teissie J
    : Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery. Gene Ther 12: 246-251, 2005.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Akaneya Y,
    2. Jiang B,
    3. Tsumoto T
    : RNAi-induced gene silencing by local electroporation in targeting brain region. J Neurophysiol 93: 594-602, 2005.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Inoue A,
    2. Takahashi KA,
    3. Mazda O,
    4. Terauchi R,
    5. Arai Y,
    6. Kishida T,
    7. Shin-Ya M,
    8. Asada H,
    9. Morihara T,
    10. Tonomura H,
    11. Ohashi S,
    12. Kajikawa Y,
    13. Kawahito Y,
    14. Imanishi J,
    15. Kawata M,
    16. Kubo T
    : Electro-transfer of small interfering RNA ameliorated arthritis in rats. Biochem Biophys Res Commun 336: 903-908, 2005.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Matsuda T,
    2. Cepko CL
    : Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci USA 101: 16-22, 2004.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Takabatake Y,
    2. Isaka Y,
    3. Mizui M,
    4. Kawachi H,
    5. Shimizu F,
    6. Ito T,
    7. Hori M,
    8. Imai E
    : Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther 12: 965-973, 2005.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Nakai N,
    2. Kishida T,
    3. Shin-Ya M,
    4. Imanishi J,
    5. Ueda Y,
    6. Kishimoto S,
    7. Mazda O
    : Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Ther 14: 357-365, 2007.
    OpenUrlCrossRefPubMed
    1. Golzio M,
    2. Mazzolini L,
    3. Ledoux A,
    4. Paganin A,
    5. Izard M,
    6. Hellaudais L,
    7. Bieth A,
    8. Pillaire MJ,
    9. Cazaux C,
    10. Hoffmann JS,
    11. Couderc B,
    12. Teissie J
    : In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery. Gene Ther 14: 752-759, 2007.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Takei Y,
    2. Nemoto T,
    3. Mu P,
    4. Fujishima T,
    5. Ishimoto T,
    6. Hayakawa Y,
    7. Yuzawa Y,
    8. Matsuo S,
    9. Muramatsu T,
    10. Kadomatsu K
    : In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency. Mol Cancer Ther 7: 211-221, 2008.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Lewis DL,
    2. Hagstrom JE,
    3. Loomis AG,
    4. Wolff JA,
    5. Herweijer H
    : Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 32: 107-108, 2002.
    OpenUrlCrossRefPubMed
  32. ↵
    1. McCaffrey AP,
    2. Meuse L,
    3. Pham TT,
    4. Conklin DS,
    5. Hannon GJ,
    6. Kay MA
    : RNA interference in adult mice. Nature 418: 38-39, 2002.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Jackson AL,
    2. Linsley PS
    : Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9: 57-67, 2010.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Stenvang J,
    2. Lindow M,
    3. Kauppinen S
    : Targeting of microRNAs for therapeutics. Biochem Soc Trans 36: 1197-1200, 2008.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Ambros V
    : microRNAs: tiny regulators with great potential. Cell 107: 823-826, 2001.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Lu J,
    2. Getz G,
    3. Miska EA,
    4. Alvarez-Saavedra E,
    5. Lamb J,
    6. Peck D,
    7. Sweet-Cordero A,
    8. Ebert BL,
    9. Mak RH,
    10. Ferrando AA,
    11. Downing JR,
    12. Jacks T,
    13. Horvitz HR,
    14. Golub TR
    : MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Hernando E
    : microRNAs and cancer: role in tumorigenesis, patient classification and therapy. Clin Transl Oncol 9: 155-160, 2007.
    OpenUrlCrossRefPubMed
  38. ↵
    1. da Costa Martins PA,
    2. Salic K,
    3. Gladka MM,
    4. Armand AS,
    5. Leptidis S,
    6. El Azzouzi H,
    7. Hansen A,
    8. Coenen-de Roo CJ,
    9. Bierhuizen MF,
    10. van der Nagel R,
    11. van Kuik J,
    12. de Weger R,
    13. de Bruin A,
    14. Condorelli G,
    15. Arbones ML,
    16. Eschenhagen T,
    17. De Windt LJ
    : MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol 12: 1220-1227, 2010.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Long J,
    2. Wang Y,
    3. Wang W,
    4. Chang BH,
    5. Danesh FR
    : Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem 285: 23457-23465, 2010.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. Ji Q,
    2. Hao X,
    3. Meng Y,
    4. Zhang M,
    5. Desano J,
    6. Fan D,
    7. Xu L
    : Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 8: 266, 2008.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Matsubara H,
    2. Takeuchi T,
    3. Nishikawa E,
    4. Yanagisawa K,
    5. Hayashita Y,
    6. Ebi H,
    7. Yamada H,
    8. Suzuki M,
    9. Nagino M,
    10. Nimura Y,
    11. Osada H,
    12. Takahashi T
    : Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 26: 6099-6105, 2007.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Dalmay T
    : MicroRNAs and cancer. J Intern Med 263: 366-375, 2008.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Care A,
    2. Catalucci D,
    3. Felicetti F,
    4. Bonci D,
    5. Addario A,
    6. Gallo P,
    7. Bang ML,
    8. Segnalini,
    9. Gu Y,
    10. Dalton ND,
    11. Elia L,
    12. Latronico MV,
    13. Hoydal M,
    14. Autore C,
    15. Russo MA,
    16. Dorn GW 2nd.,
    17. Ellingsen O,
    18. Ruiz-Lozano P,
    19. Peterson KL,
    20. Croce CM,
    21. Peschle C,
    22. Condorelli G
    : MicroRNA-133 controls cardiac hypertrophy. Nat Med 13: 613-618, 2007.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Mercatelli N,
    2. Coppola V,
    3. Bonci D,
    4. Miele F,
    5. Costantini A,
    6. Guadagnoli M,
    7. Bonanno E,
    8. Muto G,
    9. Frajese GV,
    10. De Maria R,
    11. Spagnoli LG,
    12. Farace MG,
    13. Ciafre SA
    : The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 3: e4029, 2008.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Clape C,
    2. Fritz V,
    3. Henriquet C,
    4. Apparailly F,
    5. Fernandez PL,
    6. Iborra F,
    7. Avances C,
    8. Villalba M,
    9. Culine S,
    10. Fajas L
    : miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One 4: e7542, 2009.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Corey DR
    : Chemical modification: the key to clinical application of RNA interference? J Clin Invest 117: 3615-3622, 2007.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Braasch DA,
    2. Jensen S,
    3. Liu Y,
    4. Kaur K,
    5. Arar K,
    6. White MA,
    7. Corey DR
    : RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42: 7967-7975, 2003.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Kumar R,
    2. Singh SK,
    3. Koshkin AA,
    4. Rajwanshi VK,
    5. Meldgaard M,
    6. Wengel J
    : The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2’-thio-LNA. Bioorg Med Chem Lett 8: 2219-2222, 1998.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Kaur H,
    2. Babu BR,
    3. Maiti S
    : Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA). Chem Rev 107: 4672-4697, 2007.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Crinelli R,
    2. Bianchi M,
    3. Gentilini L,
    4. Magnani M
    : Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res 30: 2435-2443, 2002.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Wahlestedt C,
    2. Salmi P,
    3. Good L,
    4. Kela J,
    5. Johnsson T,
    6. Hokfelt T,
    7. Broberger C,
    8. Porreca F,
    9. Lai J,
    10. Ren K,
    11. Ossipov M,
    12. Koshkin A,
    13. Jakobsen N,
    14. Skouv J,
    15. Oerum H,
    16. Jacobsen MH,
    17. Wengel J
    : Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 97: 5633-5638, 2000.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Lanford RE,
    2. Hildebrandt-Eriksen ES,
    3. Petri A,
    4. Persson R,
    5. Lindow M,
    6. Munk ME,
    7. Kauppinen S,
    8. Orum H
    : Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198-201, 2010.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Paganin-Gioanni A,
    2. Bellard E,
    3. Escoffre JM,
    4. Rols MP,
    5. Teissie J,
    6. Golzio M
    : Direct visualization at the single-cell level of siRNA electrotransfer into cancer cells. Proc Natl Acad Sci USA 108: 10443-10447, 2011.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Paganin-Gioanni A,
    2. Bellard E,
    3. Couderc B,
    4. Teissie J,
    5. Golzio M
    : Tracking in vitro and in vivo siRNA electrotransfer in tumor cells. J RNAi Gene Silencing 4: 281-288, 2008.
    OpenUrlPubMed
  55. ↵
    1. Golzio M,
    2. Teissie J,
    3. Rols MP
    : Direct visualization at the single-cell level of electrically mediated gene delivery. Proc Natl Acad Sci USA 99: 1292-1297, 2002.
    OpenUrlAbstract/FREE Full Text
  56. ↵
    1. Escoffre JM,
    2. Portet T,
    3. Wasungu L,
    4. Teissie J,
    5. Dean D,
    6. Rols MP
    : What is (still not) known of the mechanism by which electroporation mediates gene transfer and expression in cells and tissues. Mol Biotechnol 41: 286-295, 2009.
    OpenUrlCrossRefPubMed
  57. ↵
    1. Puc M,
    2. Kotnik T,
    3. Mir LM,
    4. Miklavcic D
    : Quantitative model of small molecules uptake after in vitro cell electropermeabilization. Bioelectrochemistry 60: 1-10, 2003.
    OpenUrlCrossRefPubMed
  58. ↵
    1. Braasch DA,
    2. Liu Y,
    3. Corey DR
    : Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res 30: 5160-5167, 2002.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    1. Corsten MF,
    2. Miranda R,
    3. Kasmieh R,
    4. Krichevsky AM,
    5. Weissleder R,
    6. Shah K
    : MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 67: 8994-9000, 2007.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Kis E,
    2. Olah J,
    3. Ocsai H,
    4. Baltas E,
    5. Gyulai R,
    6. Kemeny L,
    7. Horvath AR
    : Electrochemotherapy of cutaneous metastases of melanoma a case series study and systematic review of the evidence. Dermatol Surg 37: 816-824, 2011.
    OpenUrlPubMed
  61. ↵
    1. Mir LM,
    2. Devauchelle P,
    3. Quintin-Colonna F,
    4. Delisle F,
    5. Doliger S,
    6. Fradelizi D,
    7. Belehradek J Jr.,
    8. Orlowski S
    : First clinical trial of cat soft-tissue sarcomas treatment by electrochemotherapy. Br J Cancer 76: 1617-1622, 1997.
    OpenUrlPubMed
  62. ↵
    1. Rols MP,
    2. Tamzali Y,
    3. Teissie J
    : Electrochemotherapy of horses. A preliminary clinical report. Bioelectrochemistry 55: 101-105, 2002.
    OpenUrlCrossRefPubMed
  63. ↵
    1. Aihara H,
    2. Miyazaki J
    : Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16: 867-870, 1998.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Mir LM,
    2. Bureau MF,
    3. Gehl J,
    4. Rangara R,
    5. Rouy D,
    6. Caillaud JM,
    7. Delaere P,
    8. Branellec D,
    9. Schwartz B,
    10. Scherman D
    : High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 96: 4262-4267, 1999.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Dean DA
    : Nonviral gene transfer to skeletal, smooth, and cardiac muscle in living animals. Am J Physiol Cell Physiol 289: C233-245, 2005.
    OpenUrlAbstract/FREE Full Text
  66. ↵
    1. Heller R,
    2. Jaroszeski M,
    3. Atkin A,
    4. Moradpour D,
    5. Gilbert R,
    6. Wands J,
    7. Nicolau C
    : In vivo gene electroinjection and expression in rat liver. FEBS Lett 389: 225-228, 1996.
    OpenUrlCrossRefPubMed
  67. ↵
    1. Liu F,
    2. Huang L
    : Electric gene transfer to the liver following systemic administration of plasmid DNA. Gene Ther 9: 1116-1119, 2002.
    OpenUrlCrossRefPubMed
  68. ↵
    1. Titomirov AV,
    2. Sukharev S,
    3. Kistanova E
    : In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta 1088: 131-134, 1991.
    OpenUrlPubMed
  69. ↵
    1. Vandermeulen G,
    2. Staes E,
    3. Vanderhaeghen ML,
    4. Bureau MF,
    5. Scherman D,
    6. Preat V
    : Optimisation of intradermal DNA electrotransfer for immunisation. J Control Release 124: 81-87, 2007.
    OpenUrlCrossRefPubMed
  70. ↵
    1. Tupin E,
    2. Poirier B,
    3. Bureau MF,
    4. Khallou-Laschet J,
    5. Vranckx R,
    6. Caligiuri G,
    7. Gaston AT,
    8. Duong Van Huyen JP,
    9. Scherman D,
    10. Bariety J,
    11. Michel JB,
    12. Nicoletti A
    : Non-viral gene transfer of murine spleen cells achieved by in vivo electroporation. Gene Ther 10: 569-579, 2003.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Isaka Y,
    2. Yamada K,
    3. Takabatake Y,
    4. Mizui M,
    5. Miura-Tsujie M,
    6. Ichimaru N,
    7. Yazawa K,
    8. Utsugi R,
    9. Okuyama A,
    10. Hori M,
    11. Imai E,
    12. Takahara S
    : Electroporation-mediated HGF gene transfection protected the kidney against graft injury. Gene Ther 12: 815-820, 2005.
    OpenUrlPubMed
  72. ↵
    1. Saito T,
    2. Nakatsuji N
    : Efficient gene transfer into the embryonic mouse brain using in vivo electroporation. Dev Biol 240: 237-246, 2001.
    OpenUrlCrossRefPubMed
  73. ↵
    1. Khoury M,
    2. Bigey P,
    3. Louis-Plence P,
    4. Noel D,
    5. Rhinn H,
    6. Scherman D,
    7. Jorgensen C,
    8. Apparailly F
    : A comparative study on intra-articular versus systemic gene electrotransfer in experimental arthritis. J Gene Med 8: 1027-1036, 2006.
    OpenUrlPubMed
  74. ↵
    1. Bureau MF,
    2. Gehl J,
    3. Deleuze V,
    4. Mir LM,
    5. Scherman D
    : Importance of association between permeabilization and electrophoretic forces for intramuscular DNA electrotransfer. Biochim Biophys Acta 1474: 353-359, 2000.
    OpenUrlPubMed
  75. ↵
    1. Satkauskas S,
    2. Bureau MF,
    3. Puc M,
    4. Mahfoudi A,
    5. Scherman D,
    6. Miklavcic D,
    7. Mir LM
    : Mechanisms of in vivo DNA electrotransfer: respective contributions of cell electropermea-bilization and DNA electrophoresis. Mol Ther 5: 133-140, 2002.
    OpenUrlCrossRefPubMed
  76. ↵
    1. Mazeres S,
    2. Sel D,
    3. Golzio M,
    4. Pucihar G,
    5. Tamzali Y,
    6. Miklavcic D,
    7. Teissie J
    : Non invasive contact electrodes for in vivo localized cutaneous electropulsation and associated drug and nucleic acid delivery. J Control Release 134: 125-131, 2009.
    OpenUrlCrossRefPubMed
  77. ↵
    1. Gehl J,
    2. Sorensen TH,
    3. Nielsen K,
    4. Raskmark P,
    5. Nielsen SL,
    6. Skovsgaard T,
    7. Mir LM
    : In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta 1428: 233-240, 1999.
    OpenUrlPubMed
  78. ↵
    1. Gilbert RA,
    2. Jaroszeski MJ,
    3. Heller R
    : Novel electrode designs for electrochemotherapy. Biochim Biophys Acta 1334: 9-14, 1997.
    OpenUrlPubMed
  79. ↵
    1. Spugnini EP,
    2. Citro G,
    3. Porrello A
    : Rational design of new electrodes for electrochemotherapy. J Exp Clin Cancer Res 24: 245-254, 2005.
    OpenUrlPubMed
  80. ↵
    1. Pavselj N,
    2. Miklavcic D
    : A numerical model of permeabilized skin with local transport regions. IEEE Trans Biomed Eng 55: 1927-1930, 2008.
    OpenUrlPubMed
    1. Davis ME,
    2. Zuckerman JE,
    3. Choi CH,
    4. Seligson D,
    5. Tolcher A,
    6. Alabi CA,
    7. Yen Y,
    8. Heidel JD,
    9. Ribas A
    : Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070, 2010.
    OpenUrlCrossRefPubMed
    1. Aleku M,
    2. Schulz P,
    3. Keil O,
    4. Santel A,
    5. Schaeper U,
    6. Dieckhoff B,
    7. Janke O,
    8. Endruschat J,
    9. Durieux B,
    10. Roder N,
    11. Loffler K,
    12. Lange C,
    13. Fechtner M,
    14. Mopert K,
    15. Fisch G,
    16. Dames S,
    17. Arnold W,
    18. Jochims K,
    19. Giese K,
    20. Wiedenmann B,
    21. Scholz A,
    22. Kaufmann J
    : Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68: 9788-9798, 2008.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 31 (12)
Anticancer Research
Vol. 31, Issue 12
December 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Electrotransfer of RNAi-based Oligonucleotides for Oncology
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Electrotransfer of RNAi-based Oligonucleotides for Oncology
SOPHIE CHABOT, SANDRINE PELOFY, AURELIE PAGANIN-GIOANNI, JUSTIN TEISSIE, MURIEL GOLZIO
Anticancer Research Dec 2011, 31 (12) 4083-4089;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Electrotransfer of RNAi-based Oligonucleotides for Oncology
SOPHIE CHABOT, SANDRINE PELOFY, AURELIE PAGANIN-GIOANNI, JUSTIN TEISSIE, MURIEL GOLZIO
Anticancer Research Dec 2011, 31 (12) 4083-4089;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RNAi-based Oligonucleotides Suitable for Electrotransfer
    • Mechanism of RNAi-based Oligonucleotide Electrotransfer
    • Technical Designs
    • Conclusion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Tissue Prognostic Markers for Clear Cell Renal Cell Carcinoma Tumor-stroma Interaction: Impact on TNM Staging Parameters
  • CA9-Positive Keloid Fibroblasts: Modulator of Local Inflammation Induced by the Hypoxic and Glycolysis-enhanced Microenvironment
  • Predictive Factors for Multiple Metastases of Clear-cell Renal Cell Carcinoma
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire